Advertisement
Advertisement
VCEL
Vericel Corporation
32.84
USDSponsored
-0.10
-0.30%
May 13, 16:00 UTC -4
Closed
Pre-Market
32.90
+0.06
+0.18%
VCEL Earnings Reports
Positive Surprise Ratio
VCEL beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Jul 29, 2026
Estimate for Q2 26 (Revenue/ EPS)
$74.14M
/-$0.02
Implied change from Q1 26 (Revenue/ EPS)
+8.36%
/-83.33%
Implied change from Q2 25 (Revenue/ EPS)
+17.24%
/+100.00%
Vericel Corporation earnings per share and revenue
On May 07, 2026, VCEL reported earnings of -0.12 USD per share (EPS) for Q1 26, beating the estimate of -0.15 USD, resulting in a 24.10% surprise. Revenue reached 68.42 million, compared to an expected 64.91 million, with a 5.41% difference. The market reacted with a -4.49% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 74.14 million USD, implying an decrease of -83.33% EPS, and increase of 8.36% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Vericel Corporation's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Vericel Corporation reported EPS of -$0.12, beating estimates by 24.1%, and revenue of $68.42M, 5.41% above expectations.
How did the market react to Vericel Corporation's Q1 2026 earnings?
The stock price moved down -4.49%, changed from $36.78 before the earnings release to $35.13 the day after.
When is Vericel Corporation expected to report next?
The next earning report is scheduled for Jul 29, 2026.
What are the forecasts for Vericel Corporation's next earnings report?
Based on 8
analysts, Vericel Corporation is expected to report EPS of -$0.02 and revenue of $74.14M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement